Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Covington
Cipla
Federal Trade Commission
McKesson
US Army

Generated: September 22, 2019

DrugPatentWatch Database Preview

Patent: 6,562,957

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,562,957
Title: Genomic sequence encoding endoglin and fragments thereof
Abstract:A method of diagnosing hereditary haemorrhagic telangiectasia (HHT) which includes the steps of: obtaining a sample of genomic DNA from a patient or fetus; and determining whether the DNA contains a mutation in a gene encoding endoglin, betaglycan, TGF-.beta. type I receptor (RI), TGF-.beta. type II receptor (RII), or TGF-.beta./activin type I receptor (TSR-I), such a mutation being an indication that the patient or fetus bears a gene making the patient or fetus susceptible to HHT.
Inventor(s): Letarte; Michelle (Toronto, CA), Marchuk; Douglas A. (Chapel Hill, NC), McAllister; Kimberly (Durham, NC)
Assignee: HSC Research & Development Limited Partnership (CA) Duke University (Durham, NC)
Application Number:09/506,859
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,562,957
Patent Claims:see list of patent claims

Details for Patent 6,562,957

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Try a Free Trial HSC Research & Development Limited Partnership (CA) Duke University (Durham, NC) 2037-11-16 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Try a Free Trial HSC Research & Development Limited Partnership (CA) Duke University (Durham, NC) 2037-11-16 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Try a Free Trial HSC Research & Development Limited Partnership (CA) Duke University (Durham, NC) 2037-11-16 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Farmers Insurance
QuintilesIMS
AstraZeneca
Moodys
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.